Skip to content

Studying the Benefits of Foxtail Millet for Blood Sugar Control in Prediabetes

Understanding the Efficacy of Foxtail Millets Glycemic Response in Prediabetic Individuals and Its Associated Biomarkers - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/095798
Enrollment
16
Registered
2025-10-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E70-E88- Metabolic disorders

Interventions

Intervention1: Foxtail Millet((will be given Once in the study): Foxtail Millet-based food product, which is equivalent to 25 g of available carbohydrate, served with 200 ml of water. Intervention2:

Sponsors

CLINISYD RESEARCH GLOBAL SOLUTIONS PVT LTD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Adult age group of 25 years to 59 years Subjects, diagnosed with prediabetes as per ADA , both male and female subjects inclusive. 2 Adults Diagnosed with prediabetes 3 Fasting blood glucose levels of 100 to 125 mg per dL as per American Diabetes Association (ADA) And Glycosylated Haemoglobin (HbA1c) 5.7 to 6.4 percentage as per American Diabetes Association (ADA) 4 BMI should be between 18.5 to 24.9 kg per m2 5 Lipid profile (Total cholesterol) within normal range as applicable 6 Must be willing to give written informed consent and comply with the study procedures. 7 Subject s complete blood count parameters to be within clinically acceptable range as per the discretion by Investigator. 8.Not on antidiabetic medication

Exclusion criteria

Exclusion criteria: 1.Total cholesterol higher than normal range. 2.Subjects particularly on any special diet 3.Subjects suffering from any systemic disorders (diabetes mellitus, cardiovascular, renal, pulmonary, endocrine,or neurological disorders, ulcers, dermatologic disorders, autoimmune diseases) or severe food allergies; an activeinfectious disease (HBV, HCV, HIV) 4. current diagnosis or a history of relevant depressive episodes or of panic attacks, psychosis, bipolar or eating disorders 5.have special dietary restrictions or food allergies that would prohibit consumption of a variety of foods/beverages; 6.Patient having participated in any other clinical trial within one month prior to screening

Design outcomes

Primary

MeasureTime frame
To assess glycemic response(GR) using blood sugar levels measured at fixed intervals.Timepoint: At fixed intervals (-5, 15, 30, 45, 60, 90 and 120 min) in a day with respect to reference product

Secondary

MeasureTime frame
To assess the glycemic response(GR) of the test product assessing C-peptide levelsTimepoint: At -5min and after 120 min in a day with respect to reference product

Countries

India

Contacts

Public ContactSudha Raj

Tumkur University ,Tumkur

sudha07.raj@gmail.com9481574797

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026